Aptevo Therapeutics (NASDAQ: APVO)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.150 | -1.550 | -0.4000 | ||||
REV | 3.750M | 3.114M | -636.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Aptevo Therapeutics (NASDAQ: APVO) through any online brokerage.
Other companies in Aptevo Therapeutics’s space includes: Allena Pharma (NASDAQ:ALNA), Biocept (NASDAQ:BIOC), TransCode Therapeutics (NASDAQ:RNAZ), Diffusion Pharmaceuticals (NASDAQ:DFFN) and Ensysce Biosciences (NASDAQ:ENSC).
The latest price target for Aptevo Therapeutics (NASDAQ: APVO) was reported by Piper Sandler on Friday, May 13, 2022. The analyst firm set a price target for 20.00 expecting APVO to rise to within 12 months (a possible 417.46% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Aptevo Therapeutics (NASDAQ: APVO) is $3.865 last updated Today at July 6, 2022, 5:00 PM UTC.
There are no upcoming dividends for Aptevo Therapeutics.
Aptevo Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Aptevo Therapeutics.
Aptevo Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.